Galderma’s $1.5 Billion ZO Skin Health Purchase Signals Continued Aesthetics Consolidation
Galderma’s $1.5 billion cash acquisition of ZO Skin Health highlights consolidation in dermatology and a notable healthcare private-equity exit.
Labcorp’s $872 Million BioReference Deal Puts Diagnostics M&A in Focus
Labcorp’s agreement to acquire select BioReference assets from OPKO highlights diagnostics consolidation, valuation questions and deal-closing risk.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Tech Rout Drives Flight to Treasurys as Investors Reassess Risk in U.S. Equities
A broad technology sell-off is pushing investors toward Treasury bonds, sending yields lower and sharpening questions ab…
Aquestive’s Anaphylm NDA Resubmission Clears FDA Filing Hurdle, Setting Up AQST Catalyst
Aquestive’s accepted Anaphylm NDA resubmission gives AQST a key regulatory catalyst, with traders watching volatility ah…
Labcorp’s $872M BioReference Deal Expands Diagnostics Footprint as OPKO Reshapes Portfolio
Labcorp’s proposed BioReference asset deal could expand its diagnostics capacity while giving OPKO Health a sharper port…
Bank of America Faces $1.2 Billion Fine Over Anti-Money-Laundering Failures
A $1.2 billion US government fine puts Bank of America’s compliance controls and regulatory exposure under the market’s …
Ultragenyx’s $203 Million Voucher Sale Adds a Non-Dilutive Cash Catalyst
Ultragenyx’s planned $203 million FDA voucher sale gives $RARE a potential cash catalyst without issuing new shares.
AbbVie Stock Reaches Record High After FDA Approves Parkinson’s Drug Juvmo
AbbVie’s $283.44 record high and FDA approval of Juvmo strengthen the company’s pipeline narrative without offering a fo…
J&J Weighs Orthopedics Spinoff as Investors Reassess Its Portfolio and Valuation
Johnson & Johnson is reportedly leaning toward spinning out its hips-and-knees business, putting portfolio strategy and …
Ultragenyx’s $203 Million Voucher Sale Sets a New Cash Benchmark for Biotech
Ultragenyx’s agreed $203 million voucher sale could strengthen its balance sheet and give biotech investors a benchmark …
Galderma’s $1.5 Billion ZO Skin Health Deal Signals More Consolidation in Dermatology
Galderma’s $1.5 billion cash purchase of ZO Skin Health highlights continued consolidation across dermatology, skincare …